陸小雲(暨南大學藥學院研究員)

暨南大學藥學院研究員，博士生導師，藥學院副院長，藥學系主任，藥物化學生物學研究所副所長，國家優秀青年基金獲得者，廣東省傑出青年基金獲得者，863青年科學家項目獲得者，廣東省特支計畫青年拔尖人才，廣州市珠江新星等。

基本介紹

• 中文名：陸小雲
• 國籍：中國
• 畢業院校：中國藥科大學
• 學位/學歷：博士
• 職務：研究員
• 性別：女

基本信息

姓 名: 陸小雲

性 別: 女

職 稱: 研究員

學 歷: 博士

通訊地址: 廣州黃埔大道西601號暨南大學藥學院

簡歷

女，博士，研究員、碩士生/博士生導師，廣東省傑出青年基金獲得者，863青年科學家項目獲得者，廣東省特支計畫青年拔尖人才，廣州市珠江新星。2005年6月畢業於中國藥科大學製藥工程專業，獲學士學位；2010年6月畢業於中國藥科大學藥物化學專業，獲理學博士學位；2010年7月-2016年2月在中國科學院廣州生物醫藥與健康研究院從事科研工作，2012年1月被聘為副研究員；2016年3月加入暨南大學藥學院，從事教學科研工作。

陸小雲博士從事創新藥物先導化合物的發現研究。主要瞄準肺部疾病（肺癌和結核病等）臨床耐藥問題，集中以激酶為靶標，設計和合成具有重要生物學功能和良好成藥性的先導化合物，為創新藥物開發奠定基礎。已在Angew.Chem.Int.Ed.和J.Med.Chem等專業期刊發表第一或通訊作者SCI論文35篇，申請發明專利22項（授權10項，US專利1項），部分專利已實現轉移轉化。曾獲中國藥學會-施維雅藥物化學獎，中科院盧嘉錫青年人才獎等獎項。

研究方向

1. 新型激酶抑制劑的發現研究
2. 克服臨床耐藥的新型抗結核藥物研究

代表論著

1. Zuqin Wang,‡ Jie Wang,‡ Yongjin Wang,‡ Shuang Xiang, Hengliang Zhou, Shukai Song, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Ke Ding, Zhi-Min Zhang,* Zhang Zhang,* and Xiaoyun Lu* Structure-Based Optimization of the Third Generation Type I Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations. J. Med. Chem. 2023, 66, 12950-12965.
2. Yang Zhou,# Hang Yu,# Anna Constance Vind,# Lulu Kong,# Yiling Liu, Xiaojuan Song, Zhengchao Tu,Caihong Yun, Jeff B. Smaill, Qing-Wen Zhang, Ke Ding, Simon Bekker-Jensen,* and Xiaoyun Lu*. Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov). J. Med. Chem. 2023, 66, 11, 7405-7420.
3. Qian Li#, Tao Zhang# , Peiran Song , Linjiang Tong, Fang Feng, Jing Guo , Yang Zhou, Hua Xie, * Xiaoyun Lu. * Design, Synthesis, and Evaluation of (R)-8-((Tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as Novel Selective ACK1 Inhibitors to Combat Acquired Resistance to the Third-Generation EGFR Inhibitor. J Med Chem. 2023 May 25;66(10):6905-6921.
4. Yongjin Wang # , Yang Zhou #, Chaowei Shi #, Jiacong Liu , Guohua Lv, Huisi Huang, Shengrong Li, Liping Duan, Xinyi Zheng, Yue Liu, Haibo Zhou, Yonghua Wang, Zhengqiu Li, Ke Ding,* Pinghua Sun,* Yun Huang,* Xiaoyun Lu,* Zhi-Min Zhang.* A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria. Nat Commun.2022,13:6434.
5. Chaofan Wang, # Jie Li, # Lingzhi Qu, # Xia Tang, Xiaojuan Song, Fang Yang, Xiaojuan Chen, Qianmeng Lin, Weibin Lin, Yang Zhou, ZhengChao Tu, Yongheng Chen,* Zhang Zhang,* and Xiaoyun Lu*.Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment. J. Med. Chem. 2022, 65, 22, 15140-15164.
6. Fang Yang,# Xiaojuan Chen,# Xiaojuan Song, Raquel Ortega, Xiaojing Lin, Wuqing Deng, Jing Guo, Zhengchao Tu, Adam V. Patterson, Jeff B. Smaill,* Yongheng Chen,* and Xiaoyun Lu*. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. J. Med. Chem. 2022, 65, 21, 14809-14831.
7. Zuqin Wang#, Jie Wang#, Yongjin Wang#, Shuang Xiang , Xiaojuan Song , Zhengchao Tu , Yang Zhou, Zhi-Min Zhang*, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*.Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. J. Med. Chem. 2022, 65, 8, 6325-6337.
8. Min Shao#, Xiaojuan Chen,# Fang Yang, Xiaojuan Song, Yang Zhou, Qianmeng Lin, Ying Fu, Raquel Ortega, Xiaojing Lin, Zhengchao Tu, Adam V. Patterson, Jeff B. Smaill*, Yongheng Chen*, and Xiaoyun Lu*. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. J. Med. Chem. 2022, 65, 5113−5133
9. Liang Jiang, Yuting Wang, Qian Li, Zhengchao Tu, Sihua Zhu, Sanfang Tu*, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*. Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharm Sin B. 2021, 11, 315-1328.
10. Xiaoyun Lu*, Jeff B. Smaill, and Ke Ding*, New Promise and Opportunities for Allosteric Kinase Inhibitors. Angew. Chem. Int. Edit., 2020, 59(33), 13764-13776.